Phase 3 Obesity Trial, Recruiting NCT07035093 Sponsor: Eli Lilly and Company Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT07035093
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a history of low back pain that is mainly centred in the back (rather than coming from another part of the body)
  • People whose pain stays in the lower back or spreads only partway down the upper legs
  • People with a body mass index (BMI) of 27 or higher at the time of screening (BMI is a measure based on height and weight)
  • People who have tried at least one diet in the past to lose weight without lasting success, by their own account

Who may not be able to join:

  • People whose low back pain originates from a source other than the spine itself
  • People who have had botulinum (e.g. Botox) or steroid injections into the spine within the past year
  • People who have had trigger point injections into the spine within the past 6 months
  • People whose body weight has changed by more than 5 kilograms (about 11 pounds) in the 90 days before screening
  • People who have been taking any medications or over-the-counter products intended to reduce body weight within the 90 days before screening
  • People who have previously had, or are planning to have, surgery for obesity
  • People who have Type 1 Diabetes, Type 2 Diabetes, or any other form of diabetes

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
29 May 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇦🇷 Argentina 🇨🇦 Canada 🇵🇱 Poland 🇺🇸 United States

Primary endpoints

Change from Baseline in Pain Intensity Per Numeric Rating Scale; Percent Change from Baseline in Body Weight

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov